{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:48Z","timestamp":1784937648741,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0458"],"award-info":[{"award-number":["P3-0458"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmed.2026.108846","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:20:37Z","timestamp":1776468037000},"page":"108846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of elexacaftor\/tezacaftor\/ivacaftor on the presence of bacterial and fungal pathogens in the lower respiratory tract of children with cystic fibrosis"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3952-3608","authenticated-orcid":false,"given":"Gaja","family":"Setnikar Kimovec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-7644","authenticated-orcid":false,"given":"Katja","family":"Seme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeja","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Cvitkovi\u0107 \u0160pik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uro\u0161","family":"Krivec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Praprotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-5596","authenticated-orcid":false,"given":"Jasna","family":"Rodman Berlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.rmed.2026.108846_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmed.2026.108846_bib2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -Residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.rmed.2026.108846_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108846_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jcf.2020.12.023","article-title":"Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor","volume":"20","author":"Einarsson","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2026.108846_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.rmed.2026.108846_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2026.108846_bib9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.cmi.2025.08.012","article-title":"Change in pulmonary pathogens 3 years after elexacaftor\/tezacaftor\/ivacaftor: an observational study in the Danish cystic fibrosis cohort","volume":"31","author":"Bendixen","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"issue":"4","key":"10.1016\/j.rmed.2026.108846_bib10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1183\/23120541.01248-2024","article-title":"Respiratory infections after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis: analysis of the european cystic fibrosis society patient registry","volume":"11","author":"Pollak","year":"2025","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.rmed.2026.108846_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.108846_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71038","article-title":"Impact of Elexacaftor\/Tezacaftor\/ivacaftor on microbiology and antibiotic utilization in people with cystic fibrosis","volume":"60","author":"Williams","year":"2025","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of Elexacaftor\/Tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"7","key":"10.1016\/j.rmed.2026.108846_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ppul.23150","article-title":"Sputum induction improves detection of pathogens in children with cystic fibrosis","volume":"50","author":"Hoppe","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.108846_bib15","series-title":"ECFS CTN SOP Sputum Induction for Expectorating Older Children and Adults","author":"Hill","year":"2024"},{"key":"10.1016\/j.rmed.2026.108846_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2180-13-143","article-title":"Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis","volume":"13","author":"Le Gall","year":"2013","journal-title":"BMC Microbiol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108846_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jpeds.2007.03.002","article-title":"Diagnostic sweat testing: the cystic fibrosis foundation guidelines","volume":"151","author":"LeGrys","year":"2007","journal-title":"J. Pediatr."},{"issue":"8","key":"10.1016\/j.rmed.2026.108846_bib18","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic Society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2026.108846_bib19","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2026.108846_bib20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2026.108846_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jcf.2016.01.001","article-title":"Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis","volume":"15","author":"Zampoli","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.rmed.2026.108846_bib24","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1513\/AnnalsATS.202501-103OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in 6- to 11-Year-Olds with cystic fibrosis: an observational Study","volume":"22","author":"Pittman","year":"2025","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"4","key":"10.1016\/j.rmed.2026.108846_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jcf.2025.04.012","article-title":"LONGITUDE: an observational study of the long-term effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people aged \u226512 years with cystic fibrosis using data from the United Kingdom cystic fibrosis Registry - 2-year analysis","volume":"24","author":"Vega-Hernandez","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108846_bib26","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.rmed.2026.108846_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77246-4","article-title":"One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis","volume":"14","author":"Mianowski","year":"2024","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.rmed.2026.108846_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"issue":"7405","key":"10.1016\/j.rmed.2026.108846_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.rmed.2026.108846_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/alr.21440","article-title":"Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor","volume":"5","author":"Chang","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"issue":"5","key":"10.1016\/j.rmed.2026.108846_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01516-23","article-title":"The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms","volume":"14","author":"Jones","year":"2023","journal-title":"mBio"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:02:22Z","timestamp":1784934142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S0954611126002143"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108846","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elexacaftor\/tezacaftor\/ivacaftor on the presence of bacterial and fungal pathogens in the lower respiratory tract of children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108846"}}